Notice: This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends TOCA vs. ESPR, AMLX, SAGE, ORGO, XOMA, AKBA, CYRX, YSB, KMDA, and BMEAShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Esperion Therapeutics (ESPR), Amylyx Pharmaceuticals (AMLX), Sage Therapeutics (SAGE), Organogenesis (ORGO), XOMA (XOMA), Akebia Therapeutics (AKBA), Cryoport (CYRX), YS Biopharma (YSB), Kamada (KMDA), and Biomea Fusion (BMEA). Tocagen vs. Esperion Therapeutics Amylyx Pharmaceuticals Sage Therapeutics Organogenesis XOMA Akebia Therapeutics Cryoport YS Biopharma Kamada Biomea Fusion Esperion Therapeutics (NASDAQ:ESPR) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends. Does the MarketBeat Community favor ESPR or TOCA? Esperion Therapeutics received 369 more outperform votes than Tocagen when rated by MarketBeat users. Likewise, 69.86% of users gave Esperion Therapeutics an outperform vote while only 66.03% of users gave Tocagen an outperform vote. CompanyUnderperformOutperformEsperion TherapeuticsOutperform Votes61269.86% Underperform Votes26430.14% TocagenOutperform Votes24366.03% Underperform Votes12533.97% Which has more volatility & risk, ESPR or TOCA? Esperion Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Do analysts prefer ESPR or TOCA? Esperion Therapeutics currently has a consensus target price of $8.17, indicating a potential upside of 302.30%. Given Esperion Therapeutics' higher possible upside, equities research analysts clearly believe Esperion Therapeutics is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is ESPR or TOCA more profitable? Esperion Therapeutics has a net margin of -35.46% compared to Tocagen's net margin of -176,433.34%. Esperion Therapeutics' return on equity of 0.00% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-35.46% N/A -15.71% Tocagen -176,433.34%-327.74%-111.87% Do insiders & institutionals believe in ESPR or TOCA? 47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 21.4% of Tocagen shares are owned by institutional investors. 1.0% of Esperion Therapeutics shares are owned by insiders. Comparatively, 10.9% of Tocagen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation & earnings, ESPR or TOCA? Tocagen has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$116.33M3.42-$209.25M-$0.86-2.36Tocagen$40K2,499.54-$63.52M-$2.69-1.55 Does the media favor ESPR or TOCA? In the previous week, Esperion Therapeutics had 4 more articles in the media than Tocagen. MarketBeat recorded 4 mentions for Esperion Therapeutics and 0 mentions for Tocagen. Esperion Therapeutics' average media sentiment score of 0.13 beat Tocagen's score of 0.00 indicating that Esperion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Esperion Therapeutics Neutral Tocagen Neutral SummaryEsperion Therapeutics beats Tocagen on 13 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.98M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E Ratio-1.769.36112.5515.07Price / Sales2,499.54386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book9.295.324.645.01Net Income-$63.52M$153.56M$119.13M$225.46M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$4.18-6.1%N/A+868.7%$99.98M$40,000.00-1.7677ESPREsperion Therapeutics4.0421 of 5 stars$2.03-0.5%$8.17+302.3%+136.3%$398.35M$116.33M-2.36240Upcoming EarningsShort Interest ↓News CoverageAMLXAmylyx Pharmaceuticals4.0902 of 5 stars$5.64+4.4%$14.57+158.4%-67.0%$383.97M$380.79M-2.30200SAGESage Therapeutics4.3341 of 5 stars$6.05-0.5%$12.89+113.0%-69.3%$370.08M$86.46M-1.08690Earnings ReportAnalyst ForecastAnalyst RevisionORGOOrganogenesis4.146 of 5 stars$2.78+0.4%$4.88+75.4%+21.4%$367.23M$433.14M-21.38950News CoverageXOMAXOMA4.2516 of 5 stars$30.38+0.6%$78.50+158.4%+58.8%$355.45M$4.76M-12.2010Upcoming EarningsAKBAAkebia Therapeutics3.9242 of 5 stars$1.69+1.8%$5.75+240.2%+91.6%$355.39M$194.62M-8.05167Short Interest ↓News CoverageCYRXCryoport2.492 of 5 stars$7.15+7.4%$12.00+67.8%-24.9%$353.28M$233.26M-1.951,170Upcoming EarningsShort Interest ↑News CoverageYSBYS Biopharma1.4284 of 5 starsN/A$5.25+∞N/A$344.32M$560.76M0.00773KMDAKamada4.4414 of 5 stars$5.92+3.1%$14.50+144.9%+32.7%$340.28M$142.52M21.93360News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.7926 of 5 stars$9.04-3.5%$30.50+237.4%-13.5%$327.61MN/A-2.2550Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Esperion Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Sage Therapeutics Alternatives Organogenesis Alternatives XOMA Alternatives Akebia Therapeutics Alternatives Cryoport Alternatives YS Biopharma Alternatives Kamada Alternatives Biomea Fusion Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TOCA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
